Date: Thu, 18 Dec 1997 14:52:32 GMT Server: Stronghold/1.3.4 Ben-SSL/1.3 Apache/1.1.3 Content-type: text/html Content-length: 13195 Last-modified: Mon, 06 Oct 1997 14:20:16 GMT
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Scientific Publications |
|||||||
“Cross Clade (B,C and E Subtypes) HIV Consensus Sequence Recognition by Antibodies Based on a p17 (SF2) Synthetic Peptide” D. ZIMMERMAN, J.P. LLOYD, M.D. WINSHIP and P.S. SARIN 9th Annual Meeting National Cooperative Vaccine Development Group Bethesda MD May 1997. “Modified HGP-30 Incorporated into a Peptide Heterconjugate: A Novel Approach in HIV Vaccine Development”. D. ZIMMERMAN, J. P. LLOYD, M.D. WINSHIP and P.S. SARIN Washington DC 4th Retrovirus Meeting Jan 1997. “Immune Responses in Peripheral Blood Lymphocytes Induced by Immunizations with HIV-1 P17 Vaccine (HGP-30) Protect Scid Mice from HIV-1 Infection” J. KAHN, J.E. TALMADGE, H.GENDELMAN, S. BECKNER, M.D. WINSHIP, P.S. SARIN, P. HESELTINE. UCSF, San Francisco, CA; U. Nebraska, Omaha, NE; CEL-SCI Corporation, Alexandria, VA; USC, Los Angeles, CA. XI th International Conference on AIDS, Vancouver, B.C. July 11, 1996. "The use of peptide heteroconjugates to prime TH1 associated antibodies (IgG2a) directed against an epitope (38.G) of Mycobacterium tuberculosis which recognize the epitope in the 38KD protein."; Zimmerman, D.H., Morris, S., Rouse, D., Worthington, K.F.W., Elliott, D.A., Rosenthal, K.S.; May 1996, ASM New Orleans, LA. "Immunization with Peptide Heteroconjugates Primes a TH1 Associated Antibody (IgG2a) Response which Recognizes the Native Epitope on the 38 kDa Protein of Mycobacterium tuberculosi."; Zimmerman, D.H., Morris, S., Rouse, D., Worthington, K.F.W., Elliott, D.A., and Rosenthal, K.S.; Vacc. Res., 1996, 5:103-118. "A New Approach to T Cell Activation: Natural and Synthetic Conjugates Capable of Activating T Cells."; Zimmerman, D.H., Bergmann, K.F., Rosenthal , K.S., and Elliott, D. A. ; Vacc. Res., 1996, 5:91-102. " HIV-1 p17 synthetic peptide vaccine HGP-30: Induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice."; Sarin, P.S., Mora, C.A., Naylor, P.H., Markham, R., Schwartz, D., Kahn, J., Heseltine, P., Gazzard, B., Youle, M., Rios, A., and Goldstein, A.L.; Cellular and Molec. Biol., 1995, 41 (3): 401-407. "Leukocyte Interleukin, Injection (LI) augmentation of natural killer cells and cytolytic T-lymphocytes."; Chirigos, M.A., Talor, E., Sidwell, R.W., Burger, R.A., and Warren, R.P.; Immunopharm. and Immunotox., 1995, 17(2): 247. "The use of peptide heteroconjugates to prime TH1 or TH2 activity to an epitope of Mycobacterium tuberculostis."; Zimmerman, D., Rosenthal, K. and Elliott, D. 1995, ICAAC, San Francisco, CA. "Cytotoxic and humoral immune responses to HIV-1 p17 synthetic peptide HGP-30 in human volunteers."; Sarin, P.S., Markham, R., Schwartz, D., Naylor, P.H., Kahn, J., Heseltine, P., Gazzard, B., Youle, M., Rios, A., and Goldstein, A.L.; Vacc. Res., 1994, 3: 49-57. "Interleukins and contrasuppression induce immune regression of head and neck cancer."; Hadden, J.W., Endicott, J., Baekey, P., Skipper, P. and Hadden, E.M.: Arch. Otolar. Head Neck Surg.; 1994, 120: 395-403. "A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue subunit vaccine in seronegative subjects."; Kahn, J.D., Stites, D.P., Scillian, J.T., Murcar, N., Stryker, R., Volberding, P.A., Naylor, P.H., Goldstein, A.L., Sarin, P.S., Simmon, V.F., Wang, S.S. and Heseltine, P.; AIDS Res. Hum. Retroviruses, 1992, 8: 1321-1325. "Presence of specific antibodies to synthetic epitopes of HIV-1 gag p17 correlates with stages of HIV-1 infection in homosexuals and IV drug abusers."; Jiang, J.D., Chu, F.N., Naylor, P.H., Kirkley, J.E., Mandeli, J., Wallace, J.I., Sarin, P.S., Goldstein, A.L., Holland, J.F. and Bekesi, J.G.; J. AIDS, 1992, 5: 382-390. "Safety and immunogenicity of HGP-30: Evaluation of a synthetic HIV-1 p17 vaccine in healthy HIV seronegative volunteers."; Gazzard, B., Youle, M., MacDonald, V., O'Toole, C.M. , Stambuk, D., Rios, A., Achour, A., Zagury, D., Naylor, P.H., Sarin, P.S., and Goldstein, A.L.; Vacc. Res., 1992, 1: 129-135. "Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17 based synthetic peptide AIDS vaccine HGP-30/KLH."; Naylor, P.H., Sztein, M.B., Wada, S., Maurer, S., Hilterman, D., Kirkley, J.E., Naylor, C.W., Zook, B.C., Hitzelberg, R.A., Gibbs, C.J., Zagury, D., Achour, A., O'Toole, C., Gazzard, B., Youle, M., Rios, A., Sarin, P.S. and Goldstein, A.L.; Int. J. Immunopharm., 1991, 13 (suppl. 1): 117-127. "Diagnostic assays for human immunodeficiency virus infection and for clinical progression by use of synthetic p17 peptide epitopes."; Naylor, P.H., Heithaus, A., Kale, A., Erdos, R., Kirkley, J., and Goldstein, A.L.; Monogr. Virol., 1990, 18: 74-90. "HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17 is a target for cytotoxic lymphocytes in HIV infected individuals."; Achour, A., Picard, D., Zagury, D., Sarin, P.S., Gallo, R.C., Naylor, P.H., and Goldstein, A.L., Proc. Natl. Acad. Sci. U.S.A., 1990, 87: 7045-7049. "Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma."; Fagan, E.A., Pulley, M., Limb, A., Wolstencroft, R., Cranenburgh, C., De Vinci, C., Karani, J., Michell, M., Nunnerley, H., Zaman, S., Pizza., G., Dumonde, D., and Williams, R.; Canc. Treatm. Rev., 1989 (Supp. A), 151-160. "Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer."; Pulley, M.S., Nagendran, V., Edwards, J.M., and Dumonde, D.C.; Lymph. Res., 1986, Vol. 5 (Supp. 1).
|
|||||||
66 Canal Center Plaza Suite 510 |
![]() |
![]() |
![]() |
Home Publications Mission Shareholder Letter Product Chart Basics Questions Corporate FY96 Employment |
![]() |
![]() |
![]() |
![]() |
![]() |
|
|
|||||
66 Canal Center Plaza Suite 510 |
|||||
![]() |
![]() |
![]() |